Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DONQ52 in Active Celiac Disease (DAISY)
NCT07239336Phase 2Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of DONQ52 in celiac disease, sponsored by Chugai Pharmaceutical Co., Ltd.. Started Dec 2025; status: recruiting.
02
Drugs
DONQ52
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT07239336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07239336.